Lord Abbett Health Care FundLHCVX
Type
Mutual fund
Peer group
Global equity
Net assets
$8.1M
Expense ratio
0.68%
1-year return
+17.1%
3 years, a year
+6.2%
5 years, a year
+3.1%
Holdings
64
What it aims to do.
The Funds investment objective is to seek long-term capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| LLY Eli Lilly & Co | 8.89% |
| JOBY AstraZeneca PLC | 4.73% |
| GILD Gilead Sciences Inc | 4.25% |
| JNJ Johnson & Johnson | 3.19% |
| NKTR Nektar Therapeutics | 3.17% |
| NTRA Natera Inc | 2.91% |
| TARS Tarsus Pharmaceuticals Inc | 2.83% |
| GH Guardant Health Inc | 2.63% |
| JOBY Argenx SE | 2.49% |
| JOBY Novartis AG | 2.46% |
More on LHCVX.
- LHCVX overview
- LHCVX holdings
- LHCVX risk
- LHCVX costs
- LHCVX money in and out
- LHCVX share classes
- Compare LHCVX with other funds
Returns after fees, from the fund's SEC filings up to Apr 2026. Past returns are not a promise. Not financial advice.